The DOI matches its Crossref record; 122 of the 123 references it cites were found in a registry or an index.
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Abstract
Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth of response. Response criteria in multiple myeloma were developed to use serum and urine assessment of monoclonal proteins and bone marrow assessment (which is relatively insensitive). Given the high rates of complete response seen in patients with multiple myeloma with new treatment approaches, new response categories need to be defined that can identify responses that are deeper than those conventionally defined as complete response. Recent attempts have focused on the identification of residual tumour cells in the bone marrow using flow cytometry or gene sequencing. Furthermore, sensitive imaging techniques can be used to detect the presence of residual disease outside of the bone marrow. Combining these new methods, the International Myeloma Working Group has defined new response categories of minimal residual disease negativity, with or without imaging-based absence of extramedullary disease, to allow uniform reporting within and outside clinical trials. In this Review, we clarify several aspects of disease response assessment, along with endpoints for clinical trials, and highlight future directions for disease response assessments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although anti-BCMA therapies are approved and have shown clinical benefit for patients with relapsed or refractory multiple myeloma,4–7 relapses continue; thus, there is a need for novel therapies to expand treatment options.”
From Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) · cites this paper as [7]
In the citing paper
“The primary endpoint was objective response rate (ORR) by blinded independent central review (BICR) per IMWG criteria17.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [17]
In the citing paper
“studies are therefore evaluating deeper responses in a category termed “minimal residual disease-negative” (i.e., results below the threshold for minimal residual disease) that is prognostic with regard to a rate of disease progression in a time-toevent analysis and overall survival.5,6”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [5]
In the citing paper
“or better but have residual disease above recognized thresholds have poorer outcomes than do those who are free from detectable residual disease”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [5]
In the citing paper
“Our findings were similar to findings in the context of first-line therapy 5,6 in that results below the threshold for minimal residual disease were associated with prolonged progression-free survival among patients with relapsed or refractory multiple myeloma.”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [5]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationAttal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationTtal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citation
Research works printed but not linked: 1
- Ghimire, 2013, Incidence and survival outcomes of extramedullary myeloma, Blood, 122, 3141
Cited by
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationTeclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
Self-citationLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Self-citation
Metadata
- Authors
- Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., Dimopoulos, M., Kastritis, E., Boccadoro, M., Orlowski, R., Goldschmidt, H., Spencer, A., Hou, J., Chng, W. J., Usmani, S. Z., Zamagni, E., Shimizu, K., Jagannath, S., Johnsen, H. E., Terpos, E., Reiman, A., Kyle, R. A., Sonneveld, P., Richardson, P. G., McCarthy, P., Ludwig, H., Chen, W., Cavo, M., Harousseau, J.-L., Lentzsch, S., Hillengass, J., Palumbo, A., Orfao, A., Rajkumar, S. V., Miguel, J. S., & Avet-Loiseau, H.
- Affiliations
- Mayo Clinic (US)
- Clinica Universidad de Navarra (ES)
- Dana-Farber Cancer Institute (US)
- Cedars-Sinai Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- Emory University (US)
- Hospital Clínic de Barcelona (ES)
- National and Kapodistrian University of Athens (GR)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- The University of Texas MD Anderson Cancer Center (US)
- Heidelberg University (DE)
- The Alfred Hospital (AU)
- Shanghai Changzheng Hospital (CN)
- National University Health System (SG)
- Carolinas Healthcare System (US)
- University of Bologna (IT)
- Tokai Central Hospital (JP)
- Tisch Cancer Institute (US)
- Aalborg University Hospital (DK)
- Erasmus MC (NL)
- Roswell Park Comprehensive Cancer Center (US)
- Wilhelminen Hospital (AT)
- Columbia University (US)
- Corresponding author
- Kumar, Shaji
- ORCID
- Kumar, Shaji
- Paiva, Bruno
- Anderson, Kenneth C
- Durie, Brian
- Landgren, Ola
- Moreau, Philippe
- Munshi, Nikhil
- Lonial, Sagar
- Bladé, Joan
- Dimopoulos, Meletios
- Kastritis, Efstathios
- Boccadoro, Mario
- Orlowski, Robert
- Goldschmidt, Hartmut
- Spencer, Andrew
- Hou, Jian
- Chng, Wee Joo
- Usmani, Saad Z
- Zamagni, Elena
- Shimizu, Kazuyuki
- Jagannath, Sundar
- Johnsen, Hans E
- Terpos, Evangelos
- Kyle, Robert A
- Sonneveld, Pieter
- Richardson, Paul G
- McCarthy, Philip
- Ludwig, Heinz
- Lentzsch, Suzanne
- Hillengass, Jens
- Palumbo, Antonio
- Rajkumar, S Vincent
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 17
- Issue
- 8
- Pages
- e328-e346
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2486629951
- Semantic Scholar
- 6921d973cd0e71157eadc452e3fa3dfea1e7db4c
- Cited by
- 3,061
- References
- 123
- Citations by year
- 2026: 311 · 2025: 404 · 2024: 417 · 2023: 388 · 2022: 324 · 2021: 357 · 2020: 319 · 2019: 210 · 2018: 165 · 2017: 137 · 2016: 17
- FWCI
- 167.82
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-09-01)
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- multiple myeloma, treatment response assessment, minimal residual disease, response criteria, complete response, monoclonal protein, extramedullary disease, clinical trial endpoints, flow cytometry, gene sequencing
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Humans, Multiple Myeloma, Practice Guidelines as Topic, Neoplasm, Residual, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. https://app.cochat.ai/papers/10.1016/s1470-2045(16)30206-6
- The paper
- Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., Dimopoulos, M., Kastritis, E., Boccadoro, M., Orlowski, R., Goldschmidt, H., Spencer, A., Hou, J., Chng, W. J., Usmani, S. Z., . . . Avet-Loiseau, H. (2016). International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(16)30206-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.